Skip to content

Study · Randomized controlled trial · n = 226 · 2024

4 results

PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancer.

Matveev V, Gao X, Kopyltsov E, Luo J, Wei Q, Ye D, Zhou F, Cabri P, Houchard A, Mahmood A, Xie LP

Asia-Pacific journal of clinical oncology3 Jul 2024Cited by 1 (Europe PMC)

PMID38958195 (opens in a new tab)DOI10.1111/ajco.14101 (opens in a new tab)PepBankPUB-38958195
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In high-risk prostate cancer after prostatectomy, biochemical relapse-free survival did not differ significantly between triptorelin and surveillance.

    In plain wordsIn high-risk prostate cancer after surgery, relapse-free survival did not differ significantly between triptorelin and surveillance.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeBiochemical relapse-free survival
    Study

    n = 226

    Comparator
    Active surveillance
    Analysis
    Primary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    11.25 mg at baseline and at 3 and 6 months · 9 monthsAs given in this study (human).

    Measurements

    25th percentile BRFS
    39.1 months
    triptorelin
    25th percentile BRFS
    30 months
    surveillance

    Source sentences

    Summary
    The 25th percentile time to BRFS (95% confidence interval) was 39.1 (29.9-not estimated) months with triptorelin and 30.0 (18.6-42.1) months with surveillance (p = 0.16).
    3 context sentences
    Summary · context
    The median BRFS was not reached.
    Summary · context
    PRIORITI (NCT01753297) was a prospective, open-label, randomized, controlled, phase 4 study conducted in China and Russia.
    Summary · context
    Patients with high-risk (Gleason score ≥ 8 and/or pre-RP prostate-specific antigen [PSA] ≥ 20 ng/mL and/or primary tumor stage 3a) prostate adenocarcinoma without evidence of lymph node or distant metastases were randomized to receive triptorelin 11.25 mg at baseline (≤ 8 weeks after RP) and at 3 an…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In high-risk prostate cancer after prostatectomy, biochemical relapse risk was numerically lower with triptorelin, without statistical significance versus surveillance.

    In plain wordsIn high-risk prostate cancer after surgery, triptorelin did not significantly reduce relapse risk versus surveillance.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeBiochemical relapse risk
    Study

    n = 226

    Comparator
    Active surveillance
    Outcome group
    Tumor growth · Cancer
    Studied dose
    11.25 mg at baseline and at 3 and 6 months · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    There was evidence of a lower risk of BR with triptorelin versus surveillance but this was not statistically significant at the 5% level (p = 0.10).
    2 context sentences
    Summary · context
    PRIORITI (NCT01753297) was a prospective, open-label, randomized, controlled, phase 4 study conducted in China and Russia.
    Summary · context
    Patients with high-risk (Gleason score ≥ 8 and/or pre-RP prostate-specific antigen [PSA] ≥ 20 ng/mL and/or primary tumor stage 3a) prostate adenocarcinoma without evidence of lymph node or distant metastases were randomized to receive triptorelin 11.25 mg at baseline (≤ 8 weeks after RP) and at 3 an…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In prostate cancer patients receiving triptorelin, chemical castration persisted in 93.9% at month 9.

    In plain wordsIn prostate cancer patients receiving triptorelin, chemical castration persisted in 93.9% at month 9.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableChemical castration maintenance
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    11.25 mg at baseline and at 3 and 6 months · 9 monthsAs given in this study (human).

    Measurements

    Chemical castration
    93.9%
    month 9

    Source sentences

    Summary
    Chemical castration was maintained at month 9 in 93.9% of patients who had received triptorelin.
    2 context sentences
    Summary · context
    PRIORITI (NCT01753297) was a prospective, open-label, randomized, controlled, phase 4 study conducted in China and Russia.
    Summary · context
    Patients with high-risk (Gleason score ≥ 8 and/or pre-RP prostate-specific antigen [PSA] ≥ 20 ng/mL and/or primary tumor stage 3a) prostate adenocarcinoma without evidence of lymph node or distant metastases were randomized to receive triptorelin 11.25 mg at baseline (≤ 8 weeks after RP) and at 3 an…
  4. 04HumanRandomized controlled trialSafety outcome

    In high-risk prostate cancer after prostatectomy, triptorelin was generally well tolerated, with no unexpected safety concerns.

    In plain wordsIn high-risk prostate cancer after surgery, triptorelin was generally well tolerated, with no unexpected safety concerns.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableOverall tolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    11.25 mg at baseline and at 3 and 6 months · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    Overall, triptorelin was well tolerated and had an acceptable safety profile.
    3 context sentences
    Summary · context
    There were no unexpected safety concerns seen among the people taking triptorelin.
    Summary · context
    PRIORITI (NCT01753297) was a prospective, open-label, randomized, controlled, phase 4 study conducted in China and Russia.
    Summary · context
    Patients with high-risk (Gleason score ≥ 8 and/or pre-RP prostate-specific antigen [PSA] ≥ 20 ng/mL and/or primary tumor stage 3a) prostate adenocarcinoma without evidence of lymph node or distant metastases were randomized to receive triptorelin 11.25 mg at baseline (≤ 8 weeks after RP) and at 3 an…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.